Ribociclib plus endocrine therapy in early breast cancer
D Slamon, O Lipatov, Z Nowecki… - … England Journal of …, 2024 - Mass Medical Soc
Background Ribociclib has been shown to have a significant overall survival benefit in
patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 …
patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 …
[HTML][HTML] The Role of CD4/6 Inhibitors in Breast Cancer Treatment
L Purohit, C Jones, T Gonzalez, A Castrellon… - International Journal of …, 2024 - mdpi.com
Over the last decade, treatment paradigms for breast cancer have undergone a renaissance,
particularly in hormone-receptor-positive/HER2-negative breast cancer. These revolutionary …
particularly in hormone-receptor-positive/HER2-negative breast cancer. These revolutionary …
Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: A systematic review of the literature
G Gentile, S Scagnoli, L Arecco, D Santini… - Cancer Treatment …, 2024 - Elsevier
The therapeutic landscape for early breast cancer (eBC) has expanded by introducing novel
anticancer agents into clinical practice. During their reproductive years, women with eBC …
anticancer agents into clinical practice. During their reproductive years, women with eBC …
To dissect or not to dissect: can we predict the presence of four or more axillary lymph node metastases in postmenopausal women with clinically node-negative …
C Farley, R Bassett, F Meric-Bernstam… - Annals of surgical …, 2023 - Springer
Background Axillary lymph node (ALN) involvement is important for prognosis and guidance
of multidisciplinary treatment of breast cancer patients. This study sought to identify …
of multidisciplinary treatment of breast cancer patients. This study sought to identify …
[HTML][HTML] The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
H Schäffler, F Mergel, K Pfister, S Lukac, A Fink… - International Journal of …, 2023 - mdpi.com
The NATALEE study showed a significant benefit in invasive disease-free survival (iDFS) for
patients with HR+/HER2− early breast cancer (eBC) at intermediate and high risk of …
patients with HR+/HER2− early breast cancer (eBC) at intermediate and high risk of …
A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials
I Pourmir, HK Van Halteren, R Elaidi, D Trapani… - Cancer treatment …, 2024 - Elsevier
Background The developmental workflow of the currently performed phase 1, 2 and 3
cancer trial stages lacks essential information required for the determination of the optimal …
cancer trial stages lacks essential information required for the determination of the optimal …
TP53-associated early breast cancer: new observations from a large cohort
RL Sandoval, M Bottosso, L Tianyu… - JNCI: Journal of the …, 2024 - academic.oup.com
Background A recent large, well-annotated international cohort of patients with Li-Fraumeni
syndrome and early-stage breast cancer was examined for shared features. Methods This …
syndrome and early-stage breast cancer was examined for shared features. Methods This …
Highlights of ASCO 2023
AI Neugut, SE Bates - The Oncologist, 2023 - academic.oup.com
Highlights of ASCO 2023 | The Oncologist | Oxford Academic Skip to Main Content
Advertisement Oxford Academic Journals Books Search Menu Information Account Menu …
Advertisement Oxford Academic Journals Books Search Menu Information Account Menu …
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX …
T Link, JU Blohmer, WD Schmitt, JD Kuhlmann… - Clinical Cancer …, 2023 - AACR
Abstract Purpose: The GeparX study investigated whether denosumab as add-on treatment
to nab-paclitaxel–based neoadjuvant chemotherapy (NACT) with two different schedules …
to nab-paclitaxel–based neoadjuvant chemotherapy (NACT) with two different schedules …
Clinical implications of the Drug-Drug interaction in cancer patients treated with innovative oncological treatments
F Santamaria, M Roberto, D Buccilli… - Critical Reviews in …, 2024 - Elsevier
In the last two-decades, innovative drugs have revolutionized cancer treatments,
demonstrating a significant improvement in overall survival. These drugs may present …
demonstrating a significant improvement in overall survival. These drugs may present …